



ECIO 2017

European Conference
on Interventional Oncology

April 23-26, 2017
Bilbao, Spain

**LEADERS IN ONCOLOGIC
INTERVENTIONS**

POCKET GUIDE

www.ecio.org



Cardiovascular and Interventional Radiological Society of Europe

2	2 Important Addresses 3 Committees 4 General Information 10 Honorary Lecture 12 Hands-on Device Training	
17	Sunday – Scientific Programme	SUN
22	Monday – Scientific Programme	MON
29	Tuesday – Scientific Programme	TUE
35	Wednesday – Scientific Programme	WED
37	Corporate Activities 39 Satellite Symposia 51 Learning Centres and Corporate Workshops 53 Hands-on Device Training Sponsors	
54	Exhibitors and Sponsors 54 Sponsors 57 Technical Exhibition, Alphabetical List 59 Technical Exhibition, Numerical List 61 Technical Exhibitors Guide	

Important Addresses

Congress Venue

Euskalduna Conference Centre

Abandoibarra, nº4
48011 Bilbao
Spain

Organising Secretariat

CIRSE Central Office

Neutorgasse 9
1010 Vienna
Austria

Phone: +43 1 904 2003
Fax: +43 1 904 2003 30
E-mail: info@cirse.org
www.ecio.org

The European Conference on Interventional Oncology is organised by CIRSE (Cardiovascular and Interventional Radiological Society of Europe).

The official congress website is: www.ecio.org

To contact the CIRSE Central Office or members of the committee, please write to info@cirse.org.

Committees

Advisory Board

Andreas Adam (UK)
Thierry de Baère (FR)
Johannes Lammer (AT)
Riccardo Lencioni (US)
Jan H. Peregrin (CZ)
Jim A. Reekers (NL)

Scientific Programme Committee

Thomas K. Helmberger (DE), Chairperson
Afshin Gangi (FR), Deputy Chairperson

José I. Bilbao (ES)
Christoph A. Binkert (CH)
Elias Brountzos (GR)
Thierry de Baère (FR)
Alban Denys (CH)
Jean-François H. Geschwind (US)
Bernd Hamm (DE)
Katerina Malagari (GR)
Philippe L. Pereira (DE)

Local Host Committee

José I. Bilbao (Pamplona), Chairperson

Alexander Jon Aguinaga (Barakaldo)
Miguel Casares (Mallorca)
Eva Criado (Sabadell)
José Luis del Cura (Bilbao)
José Javier Echevarría (Galdakao)
Enrique Esteban (Alzira)
Miguel González de Garay (Bilbao)
Javier Izquierdo (Barakaldo)
Enrique Juliá (Albacete)
Antonio López-Medina (Bilbao)
Fernando López-Zárraga (Vitoria)
Antonio Marco (Bilbao)
José Luis Miguélez Vidales (Galdakao)
Borja Peña (Bilbao)
Ignacio Terreros (Barakaldo)
José Urbano (Madrid)

General Information from A to Z

App

Let the CIRSE app take care of your congress planning. Newcomers, please download the CIRSE society app which is available for iPhone, iPad and Android (www.cirse.org/app) and install the ECIO 2017 event. If the CIRSE society app is already on your smartphone, please just install the ECIO 2017 event and have the best toolkit to plan your personal congress programme, evaluate sessions, browse the exhibition, take part in votings and submit questions to the moderators in selected sessions.



Badges

Your personalised badge is your admission card to the congress. For organisational and security reasons, badges must be worn at the congress venue at all times. A lanyard will be given to you with the congress bag. Identity checks in the congress centre may occur at any time. In case of loss, a replacement badge will be provided for an administrative charge of €80.

Certificate of Attendance

To obtain your certificate of attendance, you can choose one of the following options:

Print your certificate onsite at the congress

From 10:00 on Tuesday, April 25, you can use one of the dedicated workstations in the registration area to print your certificate. All you need is your congress badge.

Print your certificate at home

After the congress you will be able to print your certificate of attendance at www.ecio.org. All you will need is your last name and badge number. Alternatively, you could log into your personal CIRSE account at www.cirse.org with your personal log-in details.

CME Credit Allowance

CIRSE is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

ECIO 2017 is designated for up to 21 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

Coffee Breaks, Snacks & Meals

During the breaks, refreshments can be purchased at the cafe located on floor -1.

The cafe opens at 09:00.

A complimentary lunch buffet and afternoon refreshments, provided by our Diamond sponsors, will be available in the exhibition area. Lunch will be from 12:00-13:00 and the afternoon break will be from 16:30-17:00.

Disclaimer

CIRSE cannot accept any liability for the acts of the suppliers to this meeting or the attendees' safety while travelling to or from the congress. All participants are strongly advised to carry adequate travel and health insurance, as CIRSE cannot accept liability for accidents or injuries that may occur.

Disclosures

For financial disclosures and conflict of interest statements, please refer to www.ecio.org.

ESIRonline – www.esir.org

ESIRonline is the largest online presentation database for interventional radiology, featuring slides and webcasts from CIRSE meetings. With a large section covering oncology topics, ESIRonline is the ideal tool for your research and educational needs. Presentations recorded at ECIO 2017 will be integrated shortly after the meeting. Access to congress-related content is available to all CIRSE members and ECIO 2017 registered participants.

Evaluation

To complete the session evaluation and obtain credits for your attendance at ECIO 2017 sessions, please use the online evaluation system, accessible through the CIRSE mobile app (please see page 4) and at <https://eval.ctimeeting.com/ecio2017>.



Internet

A free wireless service is available to all delegates throughout the congress centre.

Network: ECIO2017

Password: ecio2017

Live and On Demand – live.ecio.org

For the first time at ECIO, all sessions are being livestreamed and are available directly on demand. This means your colleagues who could not attend can watch the lectures at the same time! If you miss a session or want to download the presentation slides, just visit the on demand area.

Mobile Phones

Please do not forget to turn your mobile phone to silent mode during the sessions.

Recording and Photographing

Please note that any form of recording, filming or photographing of presentation material during the sessions is strictly forbidden. Subject to the authors' consent, all presentation material will be made available online on CIRSE's educational platform ESIRonline.

Registration Desk – Opening Hours

Saturday, April 22	16:00-18:00
Sunday, April 23	08:00-18:00
Monday, April 24	07:30-18:00
Tuesday, April 25	07:30-18:00
Wednesday, April 26	08:00-14:00

Smoking

The ECIO Annual Meeting is a non-smoking congress. Smoking is permitted outside the congress centre only.

Speaker Centre

The Speaker Centre is located on floor -2 of the congress centre in Barria Room 2. Please note that only digital material will be allowed for oral presentations. All material must be in English and provided on a CD-ROM, DVD-ROM or USB flash drive (which is preferred) to be placed on the central server onsite. All presentation files must be uploaded at least 3 hours prior to the beginning of the corresponding session.

Computers connected to the local server allowing access to the speakers' presentations are available in every lecture room. These computers are equipped with Microsoft Windows 7 Professional and Microsoft Office 2013 Professional. Please note that speakers are not allowed to use their own laptops for their presentations.

Opening Hours

Saturday, April 22	16:00-18:00
Sunday, April 23	07:45-18:30
Monday, April 24	07:30-18:30
Tuesday, April 25	08:00-18:30
Wednesday, April 26	08:00-12:00

Sponsors and Exhibitors

Please find a floor plan of the exhibition on the inside of the back cover and a detailed list of all exhibitors and sponsors on pages 54-85.

Opening Hours

Sunday, April 23	09:30-17:30
Monday, April 24	09:30-17:30
Tuesday, April 25	09:30-17:30
Wednesday, April 26	09:30-12:30

Tourist Information and Hospitality Desk

For information regarding restaurants and excursions, please refer to the desk of our official travel partner Kuoni located in the exhibition area. Kuoni will be pleased to help you with all matters related to your stay in Bilbao.


LEADERS IN ONCOLOGIC INTERVENTIONS

ECIO 2017

LIVE AND ON DEMAND



LIVE



ON DEMAND

live.ecio.org

Can't make it to the congress?

No problem, you can watch all sessions in HD quality via our livestream!

Can't decide which session to go to?

No problem, just watch the other presentations in our On Demand area!

Did you miss any other presentations from past CIRSE congresses?

No problem, just go to ESIRonline, our online congress presentation platform at **www.esir.org**

Leaders in Oncologic Interventions

Jean Palussière

Honorary Lecturer



Dr. Jean Palussière studied medicine and graduated from Bordeaux University. Following medical school, he completed his residency in Bordeaux. His first internship was in an intensive care unit, following which he opted to pursue radiology. During different internships, he progressively became familiar with vascular and interventional radiology.

At the end of his residency, he moved to Central Africa for a one-year sabbatical, where he took part in different health missions in the equatorial forest (North Congo). He returned to Bordeaux to be an assistant for two years in the vascular radiology department under Prof. Nicolas Grenier. Towards the end of 1995, to prepare for the future launch of the interventional radiology unit at Institut Bergonié, Jean moved to Institut Gustave Roussy, Villejuif, for six months where he met Prof. Alain Roche and Dr. Thierry de Baère. These six months proved to be decisive; he gained a lot of experience in this dedicated IR department that was the first of its kind in France. As well as teaching him numerous technical skills, the remarkable organisation was a source of motivation and inspiration.

Back in Bordeaux, he started to develop IR at Institut Bergonié. In 1999, the first angiosuite was installed and in 2002, the anaesthetists agreed to work in the CT room. Soon after, the first patients were treated with radiofrequency ablation for lung tumours. Since the beginning, the close partnership with Institut Gustave Roussy and Thierry de Baère led to the creation of a common database and numerous collaborative articles. In parallel, Dr. Palussière was carrying out research on HIFU and MR thermometry in Chrit Moonen's university laboratory. Ablation in clinical practice was rapidly growing and alongside cementoplasty, became the main expertise developed in Bergonié.

In 2012, the arrival of Xavier Buy, the former right-hand man of Afshin Gangi, contributed to the growth of IR in the hospital. Now, along with Vittorio Catena, three interventional radiologists work in the department.

Dr. Palussière has been a guest speaker at different universities and conferences across Europe and the USA due to his expertise in thermal lung and breast tumour ablation. Since 2003, he has been a member of CIRSE and an active participant at the annual congress and at the ECIO meeting, where he has given countless presentations on the treatment of lung and breast tumours.

Jean Palussière is married and has 3 children. An avid outdoors-man, he could only be induced to leave the IR field by 'a life in the mountains'. Ski touring is one of his main passions.

Honorary Lecture

Metastatic colorectal cancer and percutaneous thermal ablation: a happy marriage?

Monday, April 24, 10:30-11:30
Main Auditorium (Sala A1)

Hands-on Device Training

Tumour ablation

Percutaneous ablation plays an increasingly fundamental role for the loco-regional treatment of cancer. Ablation technologies and equipment for live image guidance are developing quickly.

This Hands-on Device Training (HDT) aims to provide an overview of available technologies. Separate sessions will look at radiofrequency ablation, microwave ablation and alternative techniques, including cryoablation and other image-guided technologies.

After a short kick-off presentation by the HDT coordinators, participants will have the opportunity to learn about the specifics, as well as the safe and effective use of the available technology in a hands-on setting.

Each HDT will feature a round-table discussion with the coordinators at the end of each session allowing participants to ask questions and give feedback.

Sunday, April 23

TA-HDT 1 – Radiofrequency	10:30-12:00
TA-HDT 2 – Radiofrequency	15:00-16:30

Coordinators:

A. Gillams (London/UK), C.-M. Sommer (Stuttgart/DE)

Monday, April 24

TA-HDT 3 – Microwave	10:30-12:00
TA-HDT 4 – Microwave	15:00-16:30

Coordinators:

R.-T. Hoffmann (Dresden/DE), P.L. Pereira (Heilbronn/DE)

Tuesday, April 25

TA-HDT 5 – Alternative techniques and image guidance	10:30-12:00
---	-------------

Coordinators:

R. Bale (Innsbruck/AT), L. Crocetti (Pisa/IT)

Location

HDT Room (Sala A3)

Please note that pre-registration was necessary for the Hands-on Device Training sessions. If you have not pre-registered but are interested in participating, please arrive at the room well in advance to check availability. Participation is free of charge.

For an overview of the industry partners supporting the Hands-on Device Training sessions, please refer to page 53.

ESIRonline

A WEALTH OF IR LEARNING

CIRSE publishes all congress material on ESIRonline, the best IR resource on the web, including previous ECIO and CIRSE meetings, as well as past GEST Europe conferences and ESIR courses.

All presentations from ECIO 2017 will be added to ESIRonline shortly after the conference and can also be viewed at **live.ecio.org**.

The ESIRonline Programme Committee regularly assembles **special packages** on specific topics, bringing together:

- Congress presentations
- Expert review videos
- Guidelines
- Further reading

Access to congress-related content is available to all CIRSE members and ECIO 2017 registered participants.

Log in at www.esir.org using your **myCIRSE registration data**.



www.esir.org

Recent Interventional Oncology topic packages include:



The following Interventional Oncology topic packages will be issued after ECIO 2017:

- Early-stage HCC
- Late-stage HCC
- Oncologic management of metastatic disease



European Board of Interventional Radiology



EBIR

Special preparation courses for the EBIR

**The EBIR is a highly valuable qualification
in interventional radiology based on the
European Curriculum and Syllabus for IR.**



Sessions especially suited for EBIR preparation
are highlighted in the ECIO 2017 Scientific
Programme (pages 17-36).

**Register for the EBIR
examination taking place
in Vienna, 28 February –
1 March on the occasion
of ECR 2018.**

For application deadlines and detailed
information, please visit our website at
www.cirse.org/ebir

European Board of Interventional Radiology
c/o CIRSE
Neutorgasse 9, 1010 Vienna, Austria
ebir@cirse.org
www.cirse.org/ebir



CIRSE

Sunday, April 23



08:30-10:00, Main Auditorium (Sala A1)

Clinical Focus Session

CF 101 Colorectal cancer patients – the challenge

*Moderators: A. Cervantes (Valencia/ES),
A. Gangi (Strasbourg/FR)*

- 101.1 Demographics and need for treatment
A. Cervantes (Valencia/ES)
- 101.2 Treatment strategies according to the new ESMO guidelines
D. Arnold (Lisbon/PT)
- 101.3 Who is the ideal candidate for liver surgery?
P. Bachellier (Strasbourg/FR)
- 101.4 Invited scientific paper
- 101.5 Local ablation in oligometastatic disease
A. Gillams (London/UK)
- 101.6 Intra-arterial therapies in advanced metastases
P.L. Pereira (Heilbronn/DE)



10:30-12:00, Auditorium 2 (Barria Room 1)

Clinical Focus Session

CF 201 Immunotherapy for cancer

*Moderators: J.-F.H. Geschwind (New Haven, CT/US),
P. Sarobe (Pamplona/ES)*

- 201.1 Cancer and immune reaction
J.J. Lasarte (Pamplona/ES)
- 201.2 Immunoscore: is it more relevant than TNM?
J. Rodríguez (Pamplona/ES)
- 201.3 Checkpoint inhibitors
M. Fuchs (Munich/DE)
- 201.4 Tumour exosomes – determination of organotropic metastases
B. Costa-Silva (Lisbon/PT)
- 201.5 IO and immunotherapy in cancer
J.P. Erinjeri (New York, NY/US)



e-voting



recommended for EBIR preparation



10:30-12:00, Main Auditorium (Sala A1)

Clinical Focus Session

CF 202 Colorectal cancer and IO: where is the evidence?

*Moderators: G. Beets (Maastricht/NL),
P. Gibbs (Melbourne, VIC/AU)*

- 202.1 CLOCC trial in detail
O.M. van Delden (Amsterdam/NL)
- 202.2 Evidence for surgery as a curative treatment
A. Denys (Lausanne/CH)
- 202.3 SIFLOX trial in detail
P. Gibbs (Melbourne, VIC/AU)
- 202.4 Does progression-free survival translate into overall survival?
R. Sharma (London/UK)
- 202.5 Evidence in endpoints for IO in CRC mets
T.K. Helmberger (Munich/DE)

10:30-12:00, HDT Room (Sala A3)

Hands-on Device Training

TA-HDT 1 Tumour ablation – Radiofrequency

*Coordinators: A. Gillams (London/UK),
C.-M. Sommer (Stuttgart/DE)*

13:00-13:45, Main Auditorium (Sala A1)

SY 301 Satellite Symposium

For the detailed programme
please refer to page 39.

13:45-14:30, Main Auditorium (Sala A1)

SY 302 Satellite Symposium

For the detailed programme
please refer to page 39.



15:00-16:30, Main Auditorium (Sala A1)

Multidisciplinary Tumour Board

MTB 401 CRC metastases – beyond the guidelines

Coordinator: T.K. Helmberger (Munich/DE)

*Panellists: D.J. Breen (Southampton/UK),
A. Cervantes (Valencia/ES), T. de Baère (Villejuif/FR),
C.R. Ferrone (Boston, MA/US)*



15:00-16:30, Auditorium 2 (Barria Room 1)

Technical Focus Session

TF 402 Cutting-edge developments

*Moderators: K. Malagari (Athens/GR),
J. Ricke (Magdeburg/DE)*

- 402.1 Drug-eluting particles
R. Duran (Lausanne/CH)
- 402.2 Thermal ablation
L. Crocetti (Pisa/IT)
- 402.3 Radioembolisation
M. van den Bosch (Utrecht/NL)
- 402.4 Invited scientific paper: Antitumour magnetic hyperthermia induced by RGD functionalized Fe_3O_4 nanoparticles, in an experimental model of colorectal liver metastases
*O.K. Arriortua¹, E. Garaio¹, B. Herrero de la Parte¹,
M. Insausti^{1,2}, L. Lezama^{1,2}, F. Plazaola¹,
J. Angel García^{1,2}, J.M. Aizpurua³, M. Sagartzazu³,
M. Irazola¹, N. Etxebarria¹, I. García-Alonso¹,
A. Saiz-López⁴, J.J. Echevarria-Uraga⁴;
¹Bilbao/ES, ²Derio/ES, ³Donostia/ES, ⁴Galdakao/ES*
- 402.5 Intratumoural immunotherapy and viral therapy
L. Tselikas (Villejuif/FR)
- 402.6 Immunotherapy plus ablation or DEB-TACE
B.J. Wood (Bethesda, MD/US)



e-voting



recommended for EBIR preparation

15:00-16:30, HDT Room (Sala A3)

Hands-on Device Training

TA-HDT 2 Tumour ablation – Radiofrequency

*Coordinators: A. Gillams (London/UK),
C.-M. Sommer (Stuttgart/DE)*



17:00-18:30, Main Auditorium (Sala A1)

Clinical Focus Session

CF 501 Follow the colorectal cancer patients: quality and efficacy

*Moderators: A. Adam (London/UK),
B. Gebauer (Berlin/DE)*

- 501.1 What are the guidelines?
R. Vera (Pamplona/ES)
- 501.2 Does expensive and short-term imaging follow-up affect the outcome?
R.G.H. Beets-Tan (Amsterdam/NL)
- 501.3 PET-CT: a critical review
N. Schäfer (Lausanne/CH)
- 501.4 PRO, PCO and PREM – what do they tell us?
P. Reimer (Karlsruhe/DE)
- 501.5 Changing healthcare systems: what are convincing outcome measures?
I. Durand-Zaleski (Paris/FR)



17:00-18:30, Auditorium 2 (Barria Room 1)

Clinical Focus Session

CF 502 Getting IO into practice

*Moderators: J. Lammer (Vienna/AT),
R.A. Morgan (London/UK)*

- 502.1 Curriculum in IO
P.P. Rao (Dombivli/IN)
- 502.2 How to increase patient referral
T.F. Jakobs (Munich/DE)
- 502.3 Patient pathway in IO
J. Rieke (Magdeburg/DE)
- 502.4 Interaction with other disciplines
J.I. Bilbao (Pamplona/ES)
- 502.5 How do I promote IO services to my
administration?
R.-T. Hoffmann (Dresden/DE)

18:30-19:15, Auditorium 2 (Barria Room 1)

SY 601 Satellite Symposium

For the detailed programme
please refer to page 41.



e-voting



recommended for EBIR preparation

Monday, April 24

07:45-08:15, Auditorium 2 (Barria Room 1)

SY 701 Satellite Symposium

For the detailed programme
please refer to page 43.



08:30-10:00, Main Auditorium (Sala A1)

Clinical Focus Session

CF 801 Lung metastases

*Moderators: A. Gillams (London/UK),
U. Martens (Heilbronn/DE)*

- 801.1 Rationale for local treatment – does it help patients?
I. Gil-Bazo (Pamplona/ES)
- 801.2 Resection – current status and evidence
T. Treasure (London/UK)
- 801.3 Invited scientific paper: Multi-center study of metastatic lung tumors targeted by interventional cryoablation evaluation (SOLSTICE): preliminary safety outcomes
P.W. Eiken¹, T. de Baère², F. Deschamps², J. Palussière³, X. Buy³, M.R. Callstrom¹, D.A. Woodrum¹, F. Abtin⁴, R.D. Suh⁴, B. Pua⁵, D.C. Madoff⁵, D. Papadouris⁶, S. Bagla⁶, D.E. Dupuy⁷, T. Healey⁷, W. Moore⁸, S.B. Solomon⁵, H. Yarmohammadi⁵, H. Krebs⁹;
¹Rochester, MN/US, ²Villejuif/FR, ³Bordeaux/FR, ⁴Los Angeles, CA/US, ⁵New York, NY/US, ⁶Alexandria, VA/US, ⁷Providence, RI/US, ⁸Stony Brook, NY/US, ⁹Newnan, GA/US
- 801.4 SBRT – current status and evidence
L.M. Kenny (Brisbane, QLD/AU)
- 801.5 Thermal ablation – current status and evidence
T. de Baère (Villejuif/FR)
- 801.6 Round-table discussion

08:30-10:00, Auditorium 2 (Barria Room 1)

Clinical Focus Session

CF 802 Understanding tumour biology

*Moderators: P. Gibbs (Melbourne, VIC/AU),
N. Goldberg (Jerusalem/IL)*

- 802.1 Hypoxia and anoxia – friend or enemy?
B.J. Wood (Bethesda, MD/US)
- 802.2 IO procedures inducing tumour spread
C.T. Sofocleous (New York, NY/US)
- 802.3 Post-ablation inflammation and immune reactions – the bad
N. Goldberg (Jerusalem/IL)
- 802.4 Post-ablation inflammation and immune reactions – the good
M.H.M.G.M. den Brok (Nijmegen/NL)
- 802.5 Combined locoregional and systemic immunotherapy
L. Tselikas (Villejuif/FR)

10:30-11:30, Main Auditorium (Sala A1)

HL 901 Honorary Lecture

*Moderators: J.I. Bilbao (Pamplona/ES),
E. Brountzos (Athens/GR)*

Laudation: A. Gangi (Strasbourg/FR)

- 901.1 Metastatic colorectal cancer and percutaneous thermal ablation: a happy marriage?
J. Palussière (Bordeaux/FR)



e-voting



recommended for EBIR preparation

10:30-12:00, HDT Room (Sala A3)

Hands-on Device Training

TA-HDT 3 Tumour ablation – Microwave

*Coordinators: R.-T. Hoffmann (Dresden/DE),
P.L. Pereira (Heilbronn/DE)*

11:30-12:00, Main Auditorium (Sala A1)

Paper Session

PS 902 The best IO papers of 2016

*Moderators: J.I. Bilbao (Pamplona/ES),
E. Broutzos (Athens/GR)*

- 902.1 Yttrium-90 radioembolization for colorectal cancer liver metastases: a prospective cohort study on circulating angiogenic factors and treatment response
C.E.N.M. Rosenbaum, A.F. van den Hoven, M.N.G.J.A. Braat, M. Koopman, M.G.E.H. Lam, B.A. Zonnenberg, H.M. Verkooijen, M.A.A.J. van den Bosch; Utrecht/NL
- 902.2 Independent analysis of albumin-bilirubin grade in a 765-patient cohort treated with transarterial locoregional therapy for hepatocellular carcinoma
R. Hickey, S. Mouli, L. Kulik, K. Desai, B. Thornburg, D. Ganger, T. Baker, M. Abecassis, J. Ralph Kallini, A. Gabr, V.L. Gates, A.B. Benson III, R.J. Lewandowski, R. Salem; Chicago, IL/US
- 902.3 Pharmacokinetics, safety, and efficacy of chemoembolization with doxorubicin-loaded tightly calibrated small microspheres in patients with hepatocellular carcinoma
K. Malagari, T. Kiakidis, M. Pomoni, H. Moschouris, E. Emmanouil, T. Spiridopoulos, V. Sotirchos, S. Tandees, D. Koundouras, A. Kelekis, D. Filippiadis, A. Charokopakis, E. Bouma, A. Chatziioannou, S. Dourakis, J. Koskinas, T. Karampelas, K. Tamvakopoulos, N. Kelekis, D. Kelekis; Athens/GR

13:00-13:45, Main Auditorium (Sala A1)

SY 1001 Satellite Symposium

For the detailed programme
please refer to page 43.

13:45-14:30, Main Auditorium (Sala A1)

SY 1002 Satellite Symposium

For the detailed programme
please refer to page 45.



15:00-16:30, Auditorium 2 (Barria Room 1)

Multidisciplinary Tumour Board

MTB 1101 Lung tumours – beyond the guidelines

Coordinator: J. Palussière (Bordeaux/FR)

*Panellists: J. Aristu (Pamplona/ES),
A. Gillams (London/UK), J. Jougon (Pessac/FR),
U. Martens (Heilbronn/DE)*



e-voting



recommended for EBIR preparation



15:00-16:30, Main Auditorium (Sala A1)

Clinical Focus Session

CF 1102 IO in HCC: early and intermediate

*Moderators: R. Golfieri (Bologna/IT),
B. Sangro (Pamplona/ES)*

- 1102.1 From Barcelona to Hong Kong: the HCC classifications
B. Sangro (Pamplona/ES)
- 1102.2 What to do when on the waiting list for transplantation
V. Mazzaferro (Milan/IT)
- 1102.3 Local ablation in early stage: do we compete with surgery?
L. Crocetti (Pisa/IT)
- 1102.4 Intermediate stage: is there room for radioembolisation?
R. Salem (Chicago, IL/US)
- 1102.5 Intermediate stage: what are the indications for combined therapy?
T.F. Jakobs (Munich/DE)

15:00-16:30, HDT Room (Sala A3)

Hands-on Device Training

TA-HDT 4 Tumour ablation – Microwave

*Coordinators: R.-T. Hoffmann (Dresden/DE),
P.L. Pereira (Heilbronn/DE)*

17:00-18:30, Main Auditorium (Sala A1)

Clinical Focus Session

CF 1201 IO in HCC: what's new?

*Moderators: V. Mazzaferro (Milan/IT),
J. Urbano (Madrid/ES)*

- 1201.1 Current status of classifying HCC and tailoring therapy: an update
J.-F.H. Geschwind (New Haven, CT/US)
- 1201.2 New drugs in advanced HCC
B. Sangro (Pamplona/ES)
- 1201.3 Bland embolisation vs. drug-eluting beads: the evidence
K. Malagari (Athens/GR)
- 1201.4 RF vs. microwave in tumours up to 4 cm: the evidence
A. Denys (Lausanne/CH)
- 1201.5 Cryoablation vs. RF
P.B. Shyn (Boston, MA/US)
- 1201.6 SARAH trial – late breaking data
V. Vilgrain (Clichy/FR)
- 1201.7 Idarubicin TACE
B. Guiu (Montpellier/FR)



e-voting



recommended for EBIR preparation



17:00-18:30, Auditorium 2 (Barria Room 1)

Clinical Focus Session

CF 1202 Primary lung cancer

*Moderators: G. Bastarrika (Pamplona/ES),
J. Palussière (Bordeaux/FR)*

- 1202.1 An update of systemic therapy of NSCLC
U. Martens (Heilbronn/DE)
- 1202.2 Surgery, SBRT, local ablation: an appraisal of the
pre- and post-treatment lung function
E. Quoix (Strasbourg/FR)
- 1202.3 Invited scientific paper: Microwave ablation
for lung neoplasms: a retrospective analysis of
long-term results
*T.T. Healey, B.T. March, G. Baird, D.E. Dupuy;
Providence, RI/US*
- 1202.4 SBRT
J. Aristu (Pamplona/ES)
- 1202.5 Local ablation
X. Buy (Bordeaux/FR)
- 1202.6 Imaging follow-up of SBRT and ablation
R.D. Suh (Los Angeles, CA/US)

Tuesday, April 25



08:30-10:00, Auditorium 2 (Barria Room 1)

Clinical Focus Session

CF 1501 Breast cancer patients – the IO add-on

*Moderators: E. Aranda (Córdoba/ES),
F. Orsi (Milan/IT)*

- 1501.1 Demographics and need for treatment
A. Urrutikoetxea (San Sebastián/ES)
- 1501.2 Local treatment in metastatic breast cancer:
the oncologist's perspective
J.-E. Kurtz (Strasbourg/FR)
- 1501.3 Ablation of breast tumours
J. Palussière (Bordeaux/FR)
- 1501.4 Invited scientific paper: Percutaneous thermal
ablation of breast cancer metastases in oligo-
metastatic patients
*M. Barra¹, A. Auperin¹, A. Hakimé¹, V. Cartier¹,
V. Tacher¹, Y. Otmegzguine², L. Tselikas¹, T. de Baère¹,
F. Deschamps¹; ¹Villejuif/FR, ²Boulogne-Billancourt/FR*
- 1501.5 IO in metastatic liver disease
F. Orsi (Milan/IT)
- 1501.6 IO in metastatic bone disease
D.K. Filippiadis (Athens/GR)

08:30-10:00, Main Auditorium (Sala A1)

Video Learning Session

VL 1502 How I do it – lung, kidney, bone

*Moderator: X. Serrés (Barcelona/ES)
Commentator: D.J. Breen (Southampton/UK)*

- 1502.1 Lung cryoablation
F. Deschamps (Villejuif/FR)
- 1502.2 Kidney microwave ablation
J.L. Hinshaw (Madison, WI/US)
- 1502.3 Bone consolidation
J. Garnon (Strasbourg/FR)
- 1502.4 Thyroid radiofrequency ablation
F. Stacul (Trieste/IT)



e-voting



recommended for EBIR preparation



10:30-12:00, Auditorium 2 (Barria Room 1)

Clinical Focus Session

CF 1601 MSK tumours beyond the spine

*Moderators: M.R. Callstrom (Rochester, MN/US),
A.D. Kelekis (Athens/GR)*

- 1601.1 Bone consolidation in cancer patients:
biomechanical and surgical
P.J. Papagelopoulos (Athens/GR)
- 1601.2 Indications and limits of SBRT
S. Myrehaug (Toronto, ON/CA)
- 1601.3 Invited scientific paper: Percutaneous internal
fixation to prevent impending pathological hip
fractures: a 1-year follow-up study
*F. Deschamps¹, T. Carteret², L. Tselikas¹, B. Lapuyade²,
T. de Baère¹, F. Cornelis²; ¹Villejuif/FR, ²Bordeaux/FR*
- 1601.4 Ablation and consolidation
R.-T. Hoffmann (Dresden/DE)
- 1601.5 Management of benign bone tumours excluding
osteoid osteoma
J.W. Jennings (Saint Louis, MO/US)
- 1601.6 Treatment options for soft tissue tumours
X. Buy (Bordeaux/FR)



10:30-12:00, Main Auditorium (Sala A1)

Clinical Focus Session

CF 1602 Complication management

*Moderators: P. Reimer (Karlsruhe/DE),
O.M. van Delden (Amsterdam/NL)*

1602.1 Liver thermal ablation

L. Solbiati (Rozzano/IT)

1602.2 TACE

Y. Arai (Tokyo/JP)

1602.3 Radioembolisation

B. Peynircioglu (Ankara/TR)

1602.4 Kidney cryoablation

D.J. Breen (Southampton/UK)

1602.5 Lung ablation

R.D. Suh (Los Angeles, CA/US)

1602.6 Bone ablation

J. Garnon (Strasbourg/FR)

TUE

10:30-12:00, HDT Room (Sala A3)

Hands-on Device Training

TA-HDT 5 Tumour ablation – Alternative techniques and image guidance

*Coordinators: R. Bale (Innsbruck/AT),
L. Crocetti (Pisa/IT)*

13:00-13:45, Main Auditorium (Sala A1)

SY 1701 Satellite Symposium

For the detailed programme
please refer to page 47.

13:45-14:30, Main Auditorium (Sala A1)

SY 1702 Satellite Symposium

For the detailed programme
please refer to page 47.



e-voting



recommended for EBIR preparation



15:00-16:30, Auditorium 2 (Barria Room 1)

Clinical Focus Session

CF 1801 Genomics in cancer

*Moderators: B. Costa-Silva (Lisbon/PT),
R. Lencioni (Miami, FL/US)*

- 1801.1 Genomics – a general concept?
R.B. Corcoran (Boston, MA/US)
- 1801.2 Is genomics changing the percutaneous biopsy business?
G. Frija (Paris/FR)
- 1801.3 Radiomics in MRI
D. Bonekamp (Heidelberg/DE)
- 1801.4 Radiomics – new markers in PET-CT
N. Schäfer (Lausanne/CH)
- 1801.5 Genomics – what could it mean?
R. Lencioni (Miami, FL/US)

15:00-16:30, Main Auditorium (Sala A1)

Video Learning Session

VL 1802 How I do it – liver

*Moderator: A. Denys (Lausanne/CH)
Commentator: P.E. Huppert (Darmstadt/DE)*

- 1802.1 Complex liver thermal ablation
P. Chevallier (Nice/FR)
- 1802.2 Liver DEB-TACE
R. Golfieri (Bologna/IT)
- 1802.3 Liver balloon TACE
T. de Baère (Villejuif/FR)
- 1802.4 Liver radioembolisation
P. Reimer (Karlsruhe/DE)
- 1802.5 Portal vein and hepatic vein embolisation
R. Duran (Lausanne/CH)



17:00-18:30, Main Auditorium (Sala A1)

Clinical Focus Session

CF 1901 Spinal tumours

*Moderators: A. Gangi (Strasbourg/FR),
J.W. Jennings (Saint Louis, MO/US)*

1901.1 Spinal surgery in cancer patients

J.-P. Steib (Strasbourg/FR)

1901.2 Indications and limits of SBRT

L.M. Kenny (Brisbane, QLD/AU)

1901.3 Invited scientific paper: The Metastatic Spine Disease Multidisciplinary Working Group algorithms

*A.N. Wallace¹, C.G. Robinson¹, J. Meyer², N.D. Tran³,
A. Gangi⁴, M.R. Callstrom⁵, S.T. Chao⁶, B.A. Van Tine¹,
J.M. Morris⁵, B.M. Bruel⁷, J. Long¹, R.D. Timmerman²,
J.M. Buchowski¹, J.W. Jennings¹;*

¹Saint Louis, MO/US, ²Dallas, TX/US, ³Tampa, FL/US,

⁴Strasbourg/FR, ⁵Rochester, MN/US, ⁶Cleveland, OH/US,

⁷Houston, TX/US

1901.4 Ablation and augmentation

J.W. Jennings (Saint Louis, MO/US)

1901.5 Management of benign tumours

A.D. Kelekis (Athens/GR)

1901.6 The role of embolisation

L. Hechelhammer (St. Gallen/CH)



e-voting



recommended for EBIR preparation

17:00-18:30, Auditorium 2 (Barria Room 1)

Clinical Focus Session

CF 1902 Promoting IO evidence

*Moderators: L. Donoso (Barcelona/ES),
P.L. Pereira (Heilbronn/DE)*

1902.1 CIRT

J.I. Bilbao (Pamplona/ES)

1902.2 CIREL

P.L. Pereira (Heilbronn/DE)

1902.3 Overview ongoing studies

V. Vilgrain (Clichy/FR)

1902.4 How to bring a product to market?

N.T. Lange (Bonn/DE)

1902.5 The value of registries vs. randomised trials

G.J. Poston (Liverpool/UK)

TUE

Wednesday, April 26



08:30-10:00, Main Auditorium (Sala A1)

Clinical Focus Session

CF 2101 Kidney tumours

*Moderators: J.C. Durack (New York, NY/US),
D.K. Filippiadis (Athens/GR)*

- 2101.1 Demographics and need for treatment
J.E. Robles (Pamplona/ES)
- 2101.2 Evidence-based nephron-sparing surgery
B.W. Lagerveld (Amsterdam/NL)
- 2101.3 Evidence-based ablation vs. resection outcomes
D.J. Breen (Southampton/UK)
- 2101.4 Palliative intervention in metastatic renal tumours
M.R. Callstrom (Rochester, MN/US)
- 2101.5 The CIRSE SOP paper on RCC (cT1a)
M.E. Krokidis (Cambridge/UK)



08:30-10:00, Auditorium 2 (Barria Room 1)

Clinical Focus Session

CF 2102 Recipes for general patient management

*Moderators: P.E. Bize (Genolier/CH),
F. Orsi (Milan/IT)*

- 2102.1 Assessing the patient's general condition
M. Fuchs (Munich/DE)
- 2102.2 Analgosedation vs. ITN
R. Bale (Innsbruck/AT)
- 2102.3 Peri-interventional pain management
A. Vari (Rome/IT)
- 2102.4 Peri-interventional antibiotics
G. Maleux (Leuven/BE)
- 2102.5 Anticoagulation and anti-aggregants:
how to deal with them
J.A. Páramo (Pamplona/ES)
- 2102.6 Postembolisation syndrome management
B. Gebauer (Berlin/DE)



e-voting



recommended for EBIR preparation

10:00-10:45, Main Auditorium (Sala A1)

SY 2103 Satellite Symposium

For the detailed programme
please refer to page 49.

11:15-12:45, Main Auditorium (Sala A1)

MM 2201 Morbidity & Mortality Conference

*Coordinators: M. Burrel (Barcelona/ES),
P. Chevallier (Nice/FR)*

- 2201.1 Retrievable IVC filters: not so innocuous
E. Escalante (Barcelona/ES)
- 2201.2 How should we treat large unilobar HCC?
M. Ronot (Clichy/FR)
- 2201.3 Sizing the 'Big Thinking' in multimodality liver therapies
M. González Leyte (Madrid/ES)
- 2201.4 Takotsubo cardiomyopathy after vertebroplasty of painful vertebral metastases of malignant adrenal pheochromocytoma
V. Catena (Bordeaux/FR)
*Co-authors: X. Buy (Bordeaux/FR),
J. Palussière (Bordeaux/FR)*
- 2201.5 Cardiac tamponade: a possible complication during radiofrequency (RF) ablation of colorectal lung metastasis
R.F. Grasso (Rome/IT)
- 2201.6 Portal vein and arterial complications following pancreatic IRE: two cases and suggestions for prevention and treatment
M.R. Meijerink (Amsterdam/NL)



ECIO 2017

European Conference
on Interventional Oncology

April 23-26, 2017
Bilbao, Spain



**LEADERS IN ONCOLOGIC
INTERVENTIONS**

CORPORATE ACTIVITIES & EXHIBITION

Satellite Symposia
Learning Centres and Corporate Workshops
Hands-on Device Training Sponsors
Exhibitors and Sponsors



Cardiovascular and Interventional Radiological Society of Europe

SYMPOSIUM

Sunday 23rd April 2017



Time: 13:00 – 13:45

Location: Main Auditorium,

Euskalduna Conference Centre, Bilbao

btg-im.com

INTEGRATING ^{90}Y SIRT INTO CLINICAL PRACTICE; THE TARGETED AND PERSONALISED APPROACH

Chair: Professor Etienne Garin, Rennes, France

PROGRAMME

The current place of SIRT for the treatment of liver cancer patients; where are we now and where are we going?

Prof Etienne Garin, Rennes, France

Why do we need to personalise SIRT dosimetry?
Experiences from The Christie

Dr Jon Bell, Dr Tom Westwood, The Christie, Manchester, UK

Real life cost-effectiveness of radioembolisation
in Italy for HCC treatment

Dr Sherrie Bhoori, Prof Vincenzo Mazzaferro, Milan, Italy

 **TheraSphere®**
Power Within



Imagine where we can go.



TheraSphere™ is manufactured for Biocompatibles UK Ltd, a BTG International group company. TheraSphere is a trademark of Theragenics Corporation used under license by Biocompatibles UK Ltd. TheraSphere is a registered trademark in the US, EU and certain other territories. 'Imagine where we can go' is a trademark of BTG International Ltd. BTG and the BTG roundel logo are registered trademarks of BTG International Ltd. All rights reserved. © 2017 Biocompatibles UK Ltd. EMEA March 2017.

btg-im.com

Sunday, April 23

13:00-13:45, Main Auditorium (Sala A1)

BTG

SY 301 Integrating ^{90}Y SIRT into clinical practice; the targeted and personalised approach

Moderator: E. Garin (Rennes/FR)

- 301.1 The current place of SIRT for the treatment of liver cancer patients; where are we now and where are we going
E. Garin (Rennes/FR)
- 301.2 Why do we need to personalise SIRT dosimetry; experiences from The Christie
J. Bell (Manchester/UK), T. Westwood (Manchester/UK)
- 301.3 Real life cost-effectiveness of radioembolisation in Italy for HCC treatment
S. Bhoori (Milan/IT), V. Mazzaferro (Milan/IT)

13:45-14:30, Main Auditorium (Sala A1)

Siemens Healthineers

SY 302 Complete tumour treatment while minimising collateral damage Novel technologies in image-guided therapy

Moderator: T.J. Vogl (Frankfurt/DE)

- 302.1 Advances in 3D imaging to improve guidance and outcomes during TACE procedures
T.J. Vogl (Frankfurt/DE)
- 302.2 CT- and MR-guided tumour ablation
S. Clasen (Tübingen/DE)



Boston
Scientific

Advancing science for life™

SIZED FOR
SUCCESS

18:30-19:15, Auditorium 2 (Barria Room 1)

Boston Scientific

SY 601 Controversies in DEB-TACE: optimising embolisation and drug delivery

*Moderators: J.I. Bilbao (Pamplona/ES),
T.K. Helmberger (Munich/DE)*

601.1 Is anoxia our goal?

F. Orsi (Milan/IT)

601.2 The use of 40 μ m DEB-TACE in the treatment of HCC

G. Greco (Milan/IT)

601.3 Is drug delivery the main aim?

B. Guiu (Montpellier/FR)

TO GET TO THE RIGHT DESTINATION,
YOU HAVE TO FOLLOW THE RIGHT PATH.



SwiftNINJA® Steerable Microcatheter

- 125 cm; 2.4 – 2.9F
- 180 degree steerable tip
- Rapid selection of challenging ostia
- The wire is optional



True Form™ Reshapable Guide Wire

- 145 – 180 cm; 0.014"
- May be reshaped multiple times
- Maintains its shape during procedures



Merit.com

IOS

INTERVENTIONAL
ONCOLOGY & SPINE

Monday, April 24

07:45-08:15, Auditorium 2 (Barria Room 1)

Merit Medical

SY 701 HepaSphere™ drug-eluting Microspheres Treating colorectal and neuroendocrine mets to the liver

Moderator: S. Pluntke (Essen/DE)

- 701.1 Pharmacokinetic and safety of irinotecan loaded HepaSphere™ in CRC mets to the liver
A. Gircys (Essen/DE)
- 701.2 HepaSphere™ drug-eluting Microspheres in the treatment of neuroendocrine mets to the liver
G. Maleux (Leuven/BE)

13:00-13:45, Main Auditorium (Sala A1)

Medtronic

SY 1001 Advanced techniques in thermal ablation

Moderator: D.J. Breen (Southampton/UK)

- 1001.1 400+ Emprint cases experience: what we learned
F. Orsi (Milan/IT)
- 1001.2 Complex and unusual cases management
B. Gonçalves (Porto/PT)
- 1001.3 New technology in the treatment of bone metastasis
J. Garnon (Strasbourg/FR)

FemoSeal™



Angio-Seal™

VASCULAR CLOSURE DEVICES

Now, by

TERUMO
INTERVENTIONAL
SYSTEMS

IS63AGB1116M

www.terumo-europe.com

Angio-Seal and FemoSeal are not available for sale in all countries. This information is provided only in respect to markets where this product is approved or cleared.

Please contact your Terumo local sales representative for more information.

13:45-14:30, Main Auditorium (Sala A1)

Terumo Europe

SY 1002 GREAT DEBATE in liver intra-arterial therapies

Oil vs. polymer for the treatment of HCC?

Moderator: J.L. Calleja (Madrid/ES)

1002.1 cTACE/B-TACE

T. de Baère (Villejuif/FR)

1002.2 DEM-TACE

F. Veloso Gomes (Lisbon/PT)

Moderated discussion

To poison or to irradiate mCRC?

Moderator: H. Prenen (Leuven/BE)

1002.3 DEM-TACE

P.L. Pereira (Heilbronn/DE)

1002.4 TARE

A. Denys (Lausanne/CH)

Moderated discussion

New HCC data coming soon involving more than 1200 patients.

The three largest ever RCTs investigating selective internal radiation therapy (SIRT) and standard-of-care systemic therapy in unresectable hepatocellular carcinoma (HCC) are enrolled. Two studies comparing SIR-Spheres® Y-90 resin microspheres with sorafenib will report by mid-2017. A third study, involving combination treatment with both modalities compared with sorafenib alone, is expected to report in 2018.

Please visit our Satellite Symposium

Tuesday, April 25, at 13:45–14:30

in the Main Auditorium

SIR-Spheres® Y-90 resin microspheres –

Pushing the evidence forward for Interventional Oncology



Focusing on Quality of Survival in HCC

SIR-Spheres Y-90 microspheres are approved for use in Argentina, Australia, Brazil, Canada, the European Union (CE Mark), Switzerland, Turkey, and several countries in Asia for the treatment of unresectable liver tumours. In the US, SIR-Spheres Y-90 resin microspheres have a Pre-Market Approval (PMA) from the FDA and are indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intra-hepatic artery chemotherapy (IHAC) of FUDR (Fluoruridine).

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd

Sirtex Medical United Kingdom Ltd

Building 3, Chiswick Park, 566 Chiswick High Road, London W4 5YA, United Kingdom

www.sirtex.com

Tuesday, April 25

13:00-13:45, Main Auditorium (Sala A1)

Guerbet

SY 1701 Conventional TACE and beyond

Moderator: T.J. Vogl (Frankfurt/DE)

- 1701.1 Introduction
T.J. Vogl (Frankfurt/DE)
- 1701.2 cTACE to risk-stratify HCC patients
T.J. Vogl (Frankfurt/DE)
- 1701.3 Proof on Lipiodol® unique properties!
J.-F.H. Geschwind (New Haven, CT/US)
- 1701.4 cTACE & combined therapies: the oncologist perspective
G. Abu-Alfa (New York, NY/US)
- 1701.5 Questions
T.J. Vogl (Frankfurt/DE)

13:45-14:30, Main Auditorium (Sala A1)

Sirtex Medical Europe GmbH

SY 1702 SIR-Spheres® Y-90 resin microspheres – pushing the evidence forward for interventional oncology

Moderator: J.I. Bilbao (Pamplona/ES)

- 1702.1 Current and future data for Y-90 resin microspheres in mCRC
P. Gibbs (Melbourne, VIC/AU)
- 1702.2 Breaking news in HCC: Latest evidence for Y-90 resin microspheres
V. Vilgrain (Clichy/FR)
- 1702.3 Panel discussion: Implications of the new HCC data in clinical practice

**TOSHIBA
MEDICAL**

Canon
CANON GROUP

Infinix-i 4D CT: Push your limits in Interventional Oncology



TOSHIBA SATELLITE SYMPOSIUM

**Liver Interventional Oncology,
First European experience with
Infinix-i 4D CT.**

WEDNESDAY, APRIL 26, 2017

ROOM: MAIN AUDITORIUM, 10:00 - 10:45

Speaker:

Prof. B. Guiu

University Hospital of Montpellier, France

Chairman:

Prof. A. Denys

CHUV Lausanne, Switzerland

www.toshiba-medical.eu

Meet us at booth #13

Wednesday, April 26

10:00-10:45, Main Auditorium (Sala A1)

Toshiba Medical Systems Europe

SY 2103 Infinix-i 4D CT: push your limits in interventional oncology

Moderator: A. Denys (Lausanne/CH)

2103.1 Liver interventional oncology: first European experience with Infinix-i 4D CT

B. Guiu (Montpellier/FR)

YOUR THERMAL ABLATION PARTNER

REGISTER
YOUR
PLACE AT
THE
LEARNING
CENTRE

Scan the QR code to register or
visit booth #4 for more information.



Emprint™ Ablation System
POWERED BY THERMOSPHERE™ TECHNOLOGY



Use scan app to read or visit:
bit.ly/MedtronicECIO2017

Medtronic
Further, Together

Learning Centres and Corporate Workshops

The Learning Centres and Corporate Workshops at ECIO 2017 will provide an excellent opportunity for all congress delegates to test the latest interventional devices, gain hands-on experience with new equipment and talk to industry representatives.

Please note that CIRSE is not responsible for the information provided at the Learning Centres and Corporate Workshops.

Medtronic

Meet our experts in thermal ablation during a 45-minute interactive session at our Learning Center.

Sunday, April 23

12:00-12:45

Meet the expert: MWA lung ablation

T.J. Vogl (Frankfurt/DE)

14:30-15:15

Meet the expert: MWA kidney ablation

S. Ilyas (London/UK)

16:30-17:15

Meet the product: hands-on

Monday, April 24

10:00-10:45

Meet the expert: MWA lung ablation

T.J. Vogl (Frankfurt/DE)

11:00-11:45

Meet the expert: MWA liver ablation

M. Meier (Amsterdam/NL)

14:30-15:15

Meet the expert: RFA ablation

J. Soriano (Gerona/ES)

16:30-17:15

Meet the expert: MWA kidney ablation

S. Ilyas (London/UK)

Tuesday, April 25

10:00-10:45

Meet the expert: MWA kidney ablation

S. Ilyas (London/UK)

12:00-12:45

Meet the expert: MWA liver ablation

M. Meier (Amsterdam/NL)

14:30-15:15

Meet the expert: MWA lung ablation

T.J. Vogl (Frankfurt/DE)



Register your place at the Medtronic Learning Center by visiting the Medtronic Booth #4 or by following the instructions on the website bit.ly/MedtronicECIO2017.

Philips and BTG joint workshop

Meet the experts during a one hour interactive peer-to-peer session on advanced imaging of DC Bead LUMI™, first commercially available radiopaque drug-eluting bead.

Tuesday, April 25

15:00-16:00, HDT Room (Sala A3)

Session 1: Hands-on Workshop

Advanced imaging of DC Bead LUMI™ with Philips Live Image Guidance

16:00-17:00, HDT Room (Sala A3)

Session 2: Hands-on Workshop

Advanced imaging of DC Bead LUMI™ with Philips Live Image Guidance

To join the workshop, please register at Philips booth no. 16 or at BTG booth no. 2.

Limited to 15 participants per session.

Hands-on Device Training (HDT) Sponsors

The HDT **Tumour ablation – Radiofrequency** is kindly supported by:

- H.S. Hospital Service Spa
- Merit Medical
- Olympus Surgical Technologies Europe
- RF Medical Co., Ltd
- STARmed

The HDT **Tumour ablation – Microwave** is kindly supported by:

- AngioDynamics
- H.S. Hospital Service Spa
- NeuWave Medical
- Terumo Europe

The HDT **Tumour ablation – Alternative techniques and image guidance** is kindly supported by:


- BTG (Galil)
- CAScination AG
- Endocare, Inc
- Philips Medical Systems

For detailed information on the Hands-on Device Training sessions, please refer to pages 12-13.

For further information about the industry partners, please refer to the Technical Exhibitors Guide (pages 61-85).

If you are interested in obtaining product information outside of the Hands-on Device Training sessions, please visit the respective company booth in the exhibition area.

Diamond Sponsors



DIAMOND



Booth # **2**



Booth # **9**



Booth # **4**



Booth # **11**



Booth # **1**



Booth # **3**



Platinum | Gold | Silver Sponsors



Platinum Sponsors


Boston Scientific	Booth # 10
Toshiba Medical Systems Europe	Booth # 13

Gold Sponsor

Merit Medical	Booth # 5
---------------	------------------

Silver Sponsors

Clinical Laserthermia Systems	Booth # 12
Cook Medical	Booth # 7
H.S. Hospital Services	Booth # 14
NeuWave Medical	Booth # 20
PharmaCept	Booth # 15
Philips	Booth # 16
RF Medical	Booth # 23
Starmed	Booth # 18
Surgical Specialties	Booth # 17



Siemens Satellite Symposium

Courtesy: Universitätsklinikum Frankfurt, Germany

Visit us at
booth 11

**Complete tumor treatment while
minimizing collateral damage. Novel
technologies in image guided therapy.**

Sunday, April 23, 2017;
13:45 – 14:30; Main Auditorium

Advances in 3D imaging to improve guidance and outcomes during TACE procedures

Prof. Dr. med. Thomas J. Vogl,
Institut für Diagnostische und Interventionelle Radiologie,
Universitätsklinikum Frankfurt, Germany

CT and MR guided tumor ablation

Prof. Dr. med. Stephan Clasen,
Diagnostische und Interventionelle Radiologie,
Universitätsklinikum Tübingen, Germany

We are looking forward to welcoming you at ECIO 2017.

siemens.com/angiography

SIEMENS
Healthineers 

Technical Exhibition (Alphabetical List)


Official Name	Booth #
AngioDynamics	6
Boston Scientific	10
BTG	2
CAScination	26
Clinical Laserthermia Systems	12
Cook Medical	7
Delcath Systems	25
ECO Medical	24
Elesta	28
Encapson	22
Endocare	27
Guerbet	9
H.S. Hospital Services	14
Interventional News / BIBA	21
Medtronic	4
Merit Medical	5
NeuWave Medical	20
PharmaCept	15
Philips	16
RF Medical	23
Siemens Healthcare	11
Sirtex Medical Europe	1
Starmed	18
Surefire Medical	8
Surgical Specialties	17
Terumo Europe	3
Toshiba Medical Systems Europe	13
Wisepress Medical Bookshop	19

SONOCOAT

ultimate ultrasound visibility



When
precision
counts



ENCAPSON

ultrasound visibility for medical devices



Technical Exhibition (Numerical List)

Official Name	Booth #
Sirtex Medical Europe	1
BTG	2
Terumo Europe	3
Medtronic	4
Merit Medical	5
AngioDynamics	6
Cook Medical	7
Surefire Medical	8
Guerbet	9
Boston Scientific	10
Siemens Healthcare	11
Clinical Laserthermia Systems	12
Toshiba Medical Systems Europe	13
H.S. Hospital Services	14
PharmaCept	15
Philips	16
Surgical Specialties	17
Starmed	18
Wisepress Medical Bookshop	19
NeuWave Medical	20
Interventional News / BIBA	21
Encapson	22
RF Medical	23
ECO Medical	24
Delcath Systems	25
CAScination	26
Endocare	27
Elesta	28

DC Bead LUMI™

The first* radiopaque drug-eluting bead

A NEW LEVEL OF CONTROL



VISION

See tumour coverage during and after LUMI-TACE



PRECISION

Enhanced determination of embolisation endpoint†




ASSURANCE

Confidence in treatment success

Single-shot fluoroscopy



6-week follow-up on non-contrast CT



Complete response of 4.6cm HCC following LUMI-TACE

See more at the BTG stand or visit DCBeadLUMI.com

Reference: 1. Duran R et al. Theranostics 2016; 6(1): 28-38. *First* refers to commercial availability.

For full instructions for use, warnings and important safety information relating to DC Bead LUMI™ please visit www.dcbeadlumi.com/ifu. The images shown in this piece are based on clinical case experience with the BTG radiopaque bead product in the US. The US Food and Drug Administration on 14 December 2015 cleared this radiopaque embolic bead under the branded name "LC Bead LUMI™" for the treatment of hypervascular tumours and arteriovenous malformations. DC Bead LUMI™ has CE Mark approval as a radiopaque drug-eluting bead. In order to avoid confusion, BTG has replaced any references to LC Bead LUMI™ with DC Bead LUMI™, as it is the radiopaque nature of the product that is being demonstrated.

DC Bead LUMI™ have loading with doxorubicin (for HCC) & irinotecan (for mCRC) within their CE-Mark approved indication statement

Imagine where we can go.

DC Bead LUMI™ are manufactured by Biocompatibles UK Ltd, a BTG International group company. DC Bead and DC Bead LUMI are trademarks of Biocompatibles UK Ltd. DC Bead is a registered trademark in China, EU, Japan and Republic of Korea. 'Imagine where we can go', 'See More. Treat Smarter', BTG and the BTG roundel logo are trademarks of BTG International Ltd. BTG and the BTG roundel logo are registered trademarks in the US, EU and certain other territories. All rights reserved. © Copyright 2017 Biocompatibles UK Ltd. EM-LUM-2017-0113. EMEA. Date of preparation February 2017.



btg-im.com

Technical Exhibitors Guide

AngioDynamics, Inc

6

Haaksbergweg 75

BR 1101 Amsterdam Z-O

The Netherlands

Phone: +31 20 753 2949

E-mail: customerservice@angiodynamics.com
www.AngioDynamics.com

AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products. Visit our AngioDynamics booth and find out more about the new Solero Microwave Tissue Ablation (MTA) System. More information is available at www.AngioDynamics.com.

Biocompatibles UK Ltd, a BTG International group company

2

Lakeview, Riverside Way

Watchmoor Park, Camberley

GU15 3YL Surrey

United Kingdom

Phone: +44 1276 902 020

Fax: +44 1252 732 777

E-mail: hollie.munford@btgplc.com
www.btgplc.com


DIAMOND



BTG

At BTG we are focused on bringing to market innovative products in specialist areas of medicine to better serve doctors and patients. Our growing portfolio of interventional medicine products is designed to advance the treatment of cancer, severe emphysema, severe blood clots and varicose veins, while our specialty pharmaceuticals portfolio offers antidotes that alleviate toxicity and treat rare conditions. Healthcare is constantly evolving – so BTG never stands still. Inspired by a deep understanding of our customers' needs, we're working to meaningfully improve the lives of patients

and their healthcare experience. Our competitive advantage is our dedication to finding smart, often unconventional solutions to complex medical problems. Many of our products combine medicines, device technology and new techniques in order to deliver more targeted treatments. We also invest in clinical evidence to help demonstrate the value of our products to doctors, patients, and healthcare systems. Doing what's right for patients is what gets us to work in the morning; it's part of our DNA. By staying true to this principle and our values, we've earned a strong reputation for the quality of our products and our commitment to innovation.

Boston Scientific

2 rue René Caudron, CS 30206
78961 St Quentin en Yvelines CEDEX
France
Phone: +33 139 30 97 00
www.bostonscientific.com



10

Boston Scientific (NYSE: BSX) is a worldwide developer, manufacturer and marketer of medical devices with approximately 25,000 employees and revenue of \$7.477 billion in 2015. Mission: Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.eu and connect on Twitter (@bostonsci) and Facebook. Important numbers at a glance (as of February 4th, 2016): 1 of the world's largest medical device companies, 16,000+ patents issued; ~6,500 applications pending worldwide, \$876 million invested in R&D in 2015, ~25,000 employees worldwide, market presence in approximately 100 countries worldwide.

Businesses: for more than 35 years, Boston Scientific has advanced the practice of less-invasive medicine by providing a broad and deep portfolio of innovative products, technologies and services across a wide range of medical specialties: Interventional Cardiology, Rhythm Management, Endoscopy,

Neuromodulation, Peripheral Interventions, Urology and Pelvic Health. Patients: we support patients by collaborating with a number of patient-focused organizations, such as: the World Stroke Organization (WSO), the European Parkinson's Disease Association (EPDA), Dystonia Europe (DE), and Pain Alliance Europe (PAE). For more information, please contact Corporate Communications in Europe (Europe-MediaRelations@bsci.com).

CAScination AG

26


Steigerhubelstrasse 3
3008 Bern
Switzerland
Phone: +41 31 552 0440
E-mail: info@cascination.com
www.CAScination.com

CAScination is a global leader in stereotactic navigation and image fusion enabling safer and more effective percutaneous interventions. The company is based in Bern, Switzerland and aims to revolutionise image-guided interventions and surgeries. Our CAS-One IR system is a CE Marked and FDA approved medical device that offers a comprehensive solution for percutaneous CT-guided interventions providing support in: ablation treatment planning (needle path, multi-applicator configuration, ablation prediction), needle placement (angle and depth guidance) and treatment verification through image fusion (needle placement control, ablation validation).

Support your procedures with Cook Medical devices.

EMBOLIZATION

- 1 Retracta® Detachable Embolization Coil
- 2 Tornado® Embolization Coil
- 3 Nester® Embolization Coil



BIOPSY

- 4 Liver Access and Biopsy Needle (Transjugular)
- 5 Chiba Biopsy Needle
- 6 Quick-Core® Biopsy Needle



BILIARY INTERVENTIONS

- 7 Transluminal Biliary Biopsy Forceps Set
- 8 Biliary Drainage Catheter
- 9 Zilver 635® Biliary Self-Expanding Stent



Contact your local Cook Medical representative for more information.



cookmedical.com

Clinical Laserthermia Systems AB

Scheelevägen 2

223 81 Lund

Sweden

Phone: +46 705 90 11 40

E-mail: dan@clinicallaser.se

www.clinicallaser.se



12

Clinical Laserthermia Systems (CLS) is a Swedish medical technology company with its head office in Sweden and a subsidiary in Boston, USA. We cooperate with professional health care communities around the world to further improve image-guided thermal treatment of solid tumors in both malignant as well as benign diseases. CLS markets and sells its own TRANBERG® Thermal Therapy System and a portfolio of sterile disposable instruments for image-guided intratumoral application of thermal ablation protocols, in the European and US market. CLS has built up an experience with thermal protocols aimed at achieving local tumor destruction, through coagulative necrosis, or systemic activation of the patient's immune systems through immunogenic cell death (imILT). Throughout 2017 we are introducing additional functionalities and sterile instruments for precision ablation in MR-guided procedures.

Cook Medical

O'Halloran Road

National Technology Park

Limerick

Ireland

Phone: +353 61 334440

Fax: +353 61 334441

www.cookmedical.eu



7

A global pioneer in medical breakthroughs, Cook Medical is committed to creating effective solutions that benefit millions of patients worldwide. Today, we combine medical devices, drugs, biologic grafts and cell therapies across more than 16,000 products serving more than 40 medical specialties. Founded in 1963 by a visionary who put patient needs and ethical business practices first, Cook is a family-owned company that has created more than 10,000 jobs worldwide. For more information, visit www.cookmedical.eu.

Visit us at
booth #12



You are Invited!

TRANBERG®|Thermal Therapy System, now also for MR-guided interventions.

NEW exciting opportunity in interventional oncology.

A unique platform with integrated tissue temperature feedback that also allows for MR-based tissue temperature mapping and control of your ablation and immune stimulating interstitial thermotherapy (imILT) procedures.

Make sure to visit CLS at booth #12 for more information.



www.clinicallaser.se

 **CLS**
Innovator in Cancer Immunotherapy

Delcath Systems

25

Unit 19, Mervue Business Park
Galway
Ireland
Phone: +353 91 746200
E-mail: eglynn@delcath.com
www.chemosat.com

Delcath Systems is an interventional oncology company. At Delcath, we are committed to improving the lives of patients with primary and metastatic liver cancer. Delcath are leading the way in cancer innovation with CHEMOSAT®. CHEMOSAT®, a whole organ based therapy is designed to administer high dose chemotherapy directly to the liver, while controlling systemic exposure. Our in-house clinical trial team continues to focus on areas such as ocular melanoma liver metastases (mOM), intrahepatic cholangiocarcinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and certain other cancers that are metastatic to the liver. We believe that CHEMOSAT® could offer hope for patients who may otherwise have limited treatment options – possibly improving patient outcomes while reducing drug-related side effects worldwide. Delcath Systems, Inc. currently employs over 40 people worldwide and has sales and marketing activity in over 10 countries. Our European head office is located in Galway, Ireland. While our US headquarters are located in New York City. More information about Delcath Systems can be found by logging onto www.delcath.com.

ECO Medical

24

10th Floor, Block 2, No 305
Binjiang Plaza Jiangdong North Road
210036 Nanjing
China
Phone: +86 25 8626 2817
Fax: +86 25 8626 2777
E-mail: kelvin.w@njeco.com.cn
www.ecomicrowave.com

ECO Medical is the first company in the world that developed a microwave tumor ablation system with cooling technology, in 2002. We now have 500 installations worldwide and completed 25,000 cases in 2016. We're now promoting our microwave ablation system and microwave varicose vein system worldwide. Our intelligent system has the latest advanced technology with tumor edge and shaft temperature monitoring functions and multiple safety measures. We are deeply committed to improving patient care through our continuous innovation of medical technology and solutions.

Elesta srl.

28

Via Baldanzese, 17
50041 Calenzano (FI)
Phone: +39 055 8826807
Email: info@elesta-echolaser.com
www.elesta-echolaser.com

Elesta S.r.l. was founded in 2005 by Esaote S.p.A. (leader in the production of ultrasonic equipment) and El.En. S.p.A. (world leader in laser systems), with the aim to develop, produce and sell innovative micro-invasive interventional systems. Since 2012 Elesta S.r.l. has marketed the 'Echolaser family' products, which integrate a laser device and an ultrasonic apparatus. These products are still unique in the market today. In January 2017, Esaote S.p.a. sold his shares to an investment company based in Florence (Julia Domina Holding S.r.l.) and to private investors.

Through a long-term supply agreement, Esaote S.p.A. maintains a strong commercial relationship with Elesta S.r.l.. The Chinese branch of Esaote S.p.A. also has the exclusive Elesta S.r.l. resale of products in China, one of the most important markets in the world.

Encapson B.V.

22


Hengelosestrat 705
7521PA Enschede
The Netherlands
Phone: +31 247 110 330
E-mail: info@encapson.com

Encapson is a medical technology company with the mission to improve patient care through innovative echogenic visibility solutions for medical devices. Sono-Coat™ is a "best in the class" coating-based visibility system that significantly improves the ultrasound visibility of medical devices in the body leading to better patient outcomes. The unmatched ultrasound visibility of Sono-Coat™ enables doctors carrying out difficult minimally invasive procedures. Sono-Coat™ is a game-changing technology in situations when precision counts. It enables precise targeting of objects in deeper tissue structures (e.g. liver and kidney biopsies) and supports the physician in performing accurate, safe and error-free ultrasound-guided minimally invasive procedures.

LIPIODOL® ULTRA FLUID

Ethyl ester of iodized fatty acids of poppy seed oil

Lipiodol® efficacy & safety for improved overall survival in HCC^{1,2,3,4}



Guerbet | 
Contrast for Life

LIPIODOL® ULTRA-FLUID. Composition: Ethyl esters of iodized fatty acids of poppy seed oil 10 mL, corresponding to an iodine content of 480 mg/mL. **Indications^(*):** In diagnostic radiology - Hysterosalpingography - Ascending urethrography - Lymphography - Sialography - Fistulography and exploration of abscesses - Exploration of frontal sinuses - Pre and post-operative cholangiography. In interventional radiology - Visualization and localization (by selective intra-arterial use during CT) of liver lesions in adults with known or suspected hepatocellular carcinoma - Visualization, localization and vectorisation during Trans-Arterial Chemo-Embolisation (TACE) of hepatocellular carcinoma at intermediate stage, in adults - Selective embolization in combination with Histoacryl glue (particularly for arteriovenous malformation or aneurysms) - Selective injections of LIPIODOL® ULTRA-FLUID into the hepatic artery for diagnostic purposes where a spiral CT scan is not practical. In endocrinology - Prevention of severe cases of iodine deficiency. **Posology and method of administration^(*):** have to be adapted according to the type of examination, the territories explored, the age and weight of the patient. The volume to be administered depends on the particular requirements of the technique and the size of the patient. **Contraindications:** Hypersensitivity to LIPIODOL® ULTRA-FLUID - Confirmed hyperthyroidism - Patients with traumatic injuries, recent haemorrhage or bleeding - Hysterosalpingography during pregnancy or acute pelvic inflammation - Bronchography. In interventional radiology (Trans-Arterial Chemo-Embolisation), Administration in liver areas with dilated bile ducts unless drainage has been performed. **Special warnings and special precautions for use^(*):** There is a risk of hypersensitivity regardless of the dose administered. Lymphography: Pulmonary embolism may occur immediately or after few hours to days from inadvertent systemic vascular injection or intravascular of LIPIODOL® ULTRA-FLUID: Perform radiological monitoring during LIPIODOL® ULTRA-FLUID injection and avoid use in patients with severely impaired lung function, cardiorespiratory failure or right-sided cardiac overload. Hypersensitivity: all iodinated contrast agents can lead to minor or major hypersensitivity reactions, which can be life-threatening. These hypersensitivity reactions are of an allergic nature (known as anaphylactic reactions if they are serious) or a non-allergic nature. They can be immediate (occurring within 60 min) or delayed (not occurring until up to 7 days later). Anaphylactic reactions are immediate and can be fatal. They are dose-independent, can occur right from the first administration of the product, and are often unpredictable: avoid use in patients with a history of sensitivity to other iodinated contrast agents, bronchial asthma or allergic disorders because of an increased risk of a hypersensitivity reaction to LIPIODOL® ULTRA-FLUID. Thyroid: can cause hyperthyroidism in predisposed patients. Lymphography saturates the thyroid with iodine for several months and thyroid exploration should be performed before radiological examination. Chemo-Embolization: Trans-Arterial Chemo-Embolization is not recommended in patients with decompensated liver cirrhosis (Child-Pugh >8), advanced liver dysfunction, macroscopic invasion and/or extra-hepatic spread of the tumour. Renal insufficiency must be prevented by correct rehydration before and after the procedure. Oesophageal varices must be carefully monitored. Hepatic intra-arterial treatment can progressively cause an irreversible liver insufficiency in patients with serious liver malfunction and/or undergoing close multiple sessions. The risk of superinfection in the treated area is normally prevented by administration of antibiotics. **Embolization with glue:** An early polymerisation reaction may exceptionally occur between LIPIODOL® ULTRA-FLUID and certain surgical glues, or even certain batches of glue. Before using new batches of LIPIODOL® ULTRA-FLUID or surgical glue, the compatibility of LIPIODOL® ULTRA-FLUID and the glue must be tested in vitro. **Interaction with other medicinal products and other forms of interaction^(*):** Metformin, Beta blockers, vasoactive substances, angiotensin-converting enzyme inhibitors, angiotensin-receptor antagonists, Diuretics, Interleukin 1. **Fertility, pregnancy and lactation^(*):** LIPIODOL® ULTRA-FLUID must only be used in pregnant women if absolutely necessary and under strict medical supervision. Breastfeeding should be discontinued if LIPIODOL® ULTRA-FLUID must be used. **Effects on ability to drive and use machines:** The effects on ability to drive and to use machines have not been investigated. **Undesirable effects^(*):** most adverse effects are dose-related and dosage should therefore be kept as low as possible: hypersensitivity, anaphylactic reaction, anaphylactoid reaction, vomiting, diarrhoea, nausea, fever, pain, dyspnea, cough, hypothyroidism, hyperthyroidism, thyroiditis, pulmonary embolism, cerebral embolism, retinal vein thrombosis, lymphoedema aggravation, hepatic vein thrombosis, granuloma. **Ove dose^(*):** The total dose of LIPIODOL® ULTRA-FLUID administered must not exceed 20 mL. **Pharmacodynamic properties^(*):** Pharmacotherapeutic group: X-ray contrast media, iodinated; ATC code: V08A D01. Water-insoluble iodinated contrast medium. **Presentation^(*):** 10 mL glass ampoule, box of 1 - 10 mL glass ampoule, box of 50. **Marketing authorization holder^(*):** Guerbet - BP 57400 - F-95943 Roissy CdG cedex - FRANCE. **Information:** tel : 33 (0) 1 45 91 50 00. **Revision:** September 2, 2015.

^(*) For complete information please refer to the local Summary of Product Characteristics

^(**) Indications, volumes and presentations may differ from country to country.

Reporting of suspected adverse reactions is important as it helps to continuously assess the benefit-risk balance. Therefore, Guerbet encourages you to report any adverse reactions to your health authorities or to our local Guerbet representative.

- Ikeda M, et al., Prospective Study of Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: An Asian Cooperative Study between Japan and Korea J. Vasc. Interv. Radiol. 2013; 24: 490-500
- Lo C.M. et al. Randomized Controlled Trial of Transarterial Lipiodol Chemoembolization for Unresectable Hepatocellular Carcinoma Hepatology 2002; 35: 1164-1171
- Uvel J.M. et al. arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial The Lancet 2002; 359: 1734-1739
- Uvel J.M. et al. Systematic Review of Randomized Trials for Unresectable Hepatocellular Carcinoma: Chemoembolization Improves Survival Hepatology 2003; 37: 429-442
- EASL/EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol. 2012; 56: 908-943
- Japan Society of Hepatology, Recommendation, Chapter 5, Hepatology Research 2010; 40 (Suppl. 1) 96-112
- Brux J. & Sherman M. AASLD Practice Guidelines; American Association for Study of the Liver Diseases; Hepatology 2011; 53: 1020-1022
- Chinese guidelines 2011 edition, Chin. Clin. Oncol. 2012; 1: 10

Endocare, Inc

27

9825 Spectrum Drive, Building 3
TX 78717 Austin
United States
Phone: +1 512 314 4391
Fax: +1 512 201 6789
E-mail: international@healthtronics.com
www.healthtronics.com

Endocare, Inc. is a medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. With over 10 years of clinical experience in percutaneous cryoablation for kidney, lung, palliative pain management and other tissues, we remain committed to innovative technology that improves and extends patients' lives.

Guerbet

9

P.O.Box 57400
95943 Roissy CdG Cedex
France
Phone: +33 1 45 91 50 00
E-mail: direction.communication@guerbet-group.com
www.guerbet.com



With 90 years' experience, Guerbet is a pioneer in the contrast agent field, and is the only pharmaceutical group dedicated to medical imaging worldwide. It offers a comprehensive range of X-Ray, Magnetic Resonance Imaging (MRI) and Interventional Radiology and Theranostic (IRT) products, along with a range of injectors and related medical devices to improve the diagnosis and treatment of patients. To discover new products and ensure future growth, Guerbet invests heavily in R&D, spending around 9% of its sales each year. Guerbet (GBT) is listed on Euronext Paris (Segment B – Mid Caps) and generated €776 million in revenue in 2016. For more information about Guerbet, please visit www.guerbet.com.

HS AMICA^{plus}

Re-Thinking Ablation

1 SYSTEM 2 TECHNOLOGIES

MWA&RFA

- FREEDOM OF CHOICE
- HIGH PERFORMANCE
- OPTIMIZED CONTROL
- ENHANCED SAFETY
- EXTENDED INTERACTIVITY
- DEDICATED SOFTWARE



H.S. Hospital Service S.p.A.



14

Registered Office:

Via Zosimo, 13 – 00178 Rome ITALY

Factory: Via Angela Vacchi, 23/25 – 04011 Aprilia (LT) ITALY

Phone: +39 06 9201961

Fax: +39 06 92727871

www.hshospitalservice.com

HS Hospital Service SpA is a leading player in the interventional oncology market, from RF and MW tumor ablation systems to soft tissue and bone marrow biopsy needles, catheters, drug infusion devices and all sorts of products for surgery, interventional radiology and critical care. In the field of health technologies, success may only be achieved through excellence. We are committed to delivering excellence all the way from product design and manufacturing to post-sale customer care. We transfer know-how and expertise from industrial research to the clinical field and back. Every day we work side by side with physicians and interact with all the stakeholders in interventional oncology for better understanding and fulfilling their needs and requirements, in order to deliver to the market top level devices, with optimum performance, minimum invasiveness and unmatched usability. Let us show you our new products and projects, share information, ideas, plans and strategies for the future. Come and visit us at booth number 14.

Interventional News / BIBA

21

526 Fulham Road

SW6 5NR London

United Kingdom

www.interventionalnews.com

Interventional News is an editorially independent, expertly curated news provider that brings you the news, as it happens. With a brand new website, fortnightly newsletters, social media presence, and an app with worldwide readership, we also have a quarterly print edition for subscribers in Europe and North America. Published by BIBA Medical, Interventional News is steered by renowned editors-in-chief,

Professor Andy Adam and Dr. Brian Stainken, and reaches over 12,000 interventionalists. Interventional News contains the latest news, summaries of cutting-edge research and spotlights controversies in interventional radiology. We publish expert analysis, conference coverage and key updates on the latest products and medical device industry. Have you visited us yet? Free subscription at www.interventionalnews.com.

Medtronic

Thurgauerstrasse 54
8050 Zurich
Switzerland
Phone: +41 44 308 48 48
www.medtronic.com



DIAMOND

4

Medtronic
Further, Together

As a global leader in medical technology, services and solutions, Medtronic improves the lives and health of millions of people each year. We use our deep clinical, therapeutic and economic expertise to address the complex challenges faced by healthcare systems today. Let's take healthcare "Further, Together". Learn more at Medtronic.com.

Merit Medical

Amerikalaan 42
6199AE Maastricht
The Netherlands
Phone: +31 4335 88 222
www.merit.com



5

Founded in 1987, Merit Medical Systems, Inc. is a worldwide company engaged in the development, manufacturing and distribution of proprietary disposable medical devices, used in interventional and diagnostic procedures, particularly in cardiology, radiology, embolic therapy and endoscopy. With a global work force and cutting-edge manufacturing facilities equipped with the most advanced technology, Merit Medical consistently delivers quality products that

are backed by excellent customer service and professional expertise. We look forward to ECIO 2017 and the opportunity to present our high-performance hepatic oncology and delivery systems portfolios: HepaSpheres™ Microspheres deliver excellent objective response rates for embolisation of hepatocellular carcinoma and metastases to the liver; SwiftNINJA® is a straight tip catheter that articulates up to 180 degrees in opposing directions to rapidly select the most challenging vascular ostium; True Form™ is a 0.014" reshapable guide wire that can be shaped multiple times and maintain its shape during procedures. Our STAR™ Tumour Ablation system provides minimally invasive, localised tumour ablation for symptomatic spinal metastases, offering patients the potential for significant and immediate pain relief. The Merit Medical team will be delighted to see you at our booth and present our product portfolio.

NeuWave Medical

3529 Anderson St.

WI 53704 Madison

United States

Phone: +1 877 323 9283

Fax: +1 608 512 1509

E-mail: info@neuwave.comwww.neuwave.com

20

NeuWave Medical®, now a part of the Ethicon™ family of companies, offers the first intelligent ablation system and the only system that has it all. The versatile probe portfolio with multi-probe synchronized energy allows physicians to tailor ablations with 1, 2 or 3 probes. Ablation Confirmation™ software now offers the only integrated in-procedure confirmation to evaluate the technical success of your procedure.



neoadjuvant – adjuvant – palliative

EmboCept® S

universal temporary embolic agent

**Your ideal combination partner
for optimization of
locoregional tumor therapy**

EmboCept® S


- Biodegradable
(half-life 35 min)
- Highly tolerable
- Mixable with
various substances
- Price-effective



PlatiCept®

Cisplatin 50 mg powder

- Approved in broad spectrum
of cancer therapies
- Proved in the interventional
radiology
- Significantly higher
platinum-concentration
in tumor under
DSM-TACE
- Comparable efficacy
to anthracyclines



PharmaCept

www.pharmacept.com

PharmaCept GmbH

Bessemerstr. 82

12103 Berlin

Germany

Phone: +49 30 75 65 98 50

Fax: +49 30 75 65 98 511

E-mail: info@pharmacept.com

www.pharmacept.com



15

PharmaCept stands for a successful development of niche products and instructions in the area of cancer treatment with a special focus on research in Interventional Oncology. The main pillar of our company's development is in the field of chemoembolization therapy. On the basis of the Barcelona guidelines for the treatment of primary liver cell carcinoma, chemoembolization has become an integral part of the treatment of this illness. Increasing experience has shown that the use of permanent vascular occlusion materials promotes the development of new blood vessels which sustain tumor growth. With EmboCept® S, our biodegradable starch microspheres, these side effects can be considerably reduced. New clinical studies will now further scientifically explore the already known advantages of short-term vessel-blockage and unlimited combination with drugs, e.g. our new Cisplatin powder PlatiCept®. Cisplatin powder was the second most often used chemotherapeutic agent within the treatment of primary liver cancer, until it disappeared. It can be used as an alternative drug to doxorubicin, within a combination or after a tumor progression under anthracyclines. Our experimental data show a significant increased accumulation of platin products in the tumor tissue under the combination with starch microspheres (EmboCept® S).

Philips

Veenpluis 4-6

5684 PC Best

The Netherlands

Phone: +31 622 698 001

E-mail: fabienne.van.der.feer@philips.comwww.Philips.com

16

Enabling better health and better care at lower cost Philips is a leading health technology company focused on improving people's lives across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Applying advanced technologies and deep clinical and consumer insights, Philips delivers integrated solutions that improve people's health and enable better outcomes. Partnering with its customers, Philips seeks to transform how healthcare is delivered and experienced. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care.

RF Medical Co., Ltd.

#506, 254, Beotkkot-ro,

Geumcheon-gu

Seoul

Korea

Phone: +82 2 2108 4200

Fax: +82 2 2113 7999

E-mail: overseas@rfa.co.krwww.rfa.co.kr

23

Since 2003, RF Medical is dedicated to popularizing radio-frequency ablation treatments as a manufacturer. Our extensive product range spans from tumor ablation to varicose vein treatments. Our sophisticated technology has allowed us to spread our business to more than 50 countries and our proven quality has granted us a strong reputation on the market. As always, RF Medical strives with all its capabilities to create a healthier world by continuous investment in research and development.

Siemens Healthcare GmbH

Henkestr. 127

91052 Erlangen

Germany

Phone: +49 9131 84-0

Fax: +49 9131 84-2924

E-mail: contact.healthcare@siemens.com

www.healthcare.siemens.com



DIAMOND

SIEMENS
Healthineers

11

Siemens Healthineers is the separately managed healthcare business of Siemens AG enabling healthcare providers worldwide to meet their current challenges and to excel in their respective environments. A leader in medical technology, Siemens Healthineers is constantly developing its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services. To help customers succeed in today's dynamic healthcare marketplace, Siemens Healthineers is championing new business models that maximize opportunity and minimize risk for healthcare providers. In fiscal 2016, which ended on September 30, 2016, Siemens Healthineers generated revenue of €13.5 billion and profit of over €2.3 billion and has about 46,000 employees worldwide. Further information is available at www.siemens.com/healthineers.

Sirtex Medical Europe GmbH

Joseph-Schumpeter-Allee 33

53227 Bonn

Germany

Phone: +49 228 18407 30

Fax: +49 228 18407 35

E-mail: info@sirtex-europe.com

www.sirtex.com



DIAMOND

SIRTeX

1

Sirtex Medical is actively engaged in the field of liver-directed therapies for cancer patients. The innovative technology of Sirtex, SIR-Spheres® Y-90 resin microspheres (microscopic Yttrium-90 resin beads), is a medical device used in interventional oncology to deliver Selective Internal



Korean Engineering and Technology Advances
in **Radiofrequency Ablation** that brings you
devices specifically designed to enhance your
procedural experience and clinical results.

Booth no.18
Visit us to find out more

STARmed, the leader in Thyroid RFA!

STARmed Co.,Ltd. Korea | www.starmed4u.com

Radiation Therapy (SIRT), also known as radioembolisation, to the liver. This treatment for inoperable liver cancer delivers high doses of radiation directly to the site of tumours whilst conserving normal liver parenchyma. SIR-Spheres® microspheres were approved in 2002 for use in the treatment of a variety of unresectable liver tumours as well as in hepatocellular carcinoma within the European Union under a CE Mark. They are presently used at 306+ institutions in Europe and to date more than 70.000 treatments have been delivered worldwide. New HCC data coming soon: The three largest ever RCTs (> 1.200 patients) investigating SIRT and standard-of-care systemic therapy in unresectable hepatocellular carcinoma (HCC) are enrolled. Two studies comparing SIR-Spheres® Y-90 resin microspheres with sorafenib will report by April 2017. A third study, involving combination treatment with both modalities compared with sorafenib alone, is expected to be reported in 2018.

STARmed CO., LTD.

#402, Daebang Triplaon B, 1681
Jungsan-dong, IlsanDong-gu
410315 Goyang-si, Gyeonggi-do
Korea
Phone: +82 506 816
E-mail: info@starmed4u.com
www.starmed4u.com



18

STARmed Co., Ltd. is a young and fast growing company from South Korea, specializing in radiofrequency technology. Passionately working on the best possible RF treatment, STARmed has collaborated with a number of key opinion leaders in developing the most innovative electrodes and leading-edge RF technology specific to certain tumour types and clinical applications, in the thyroid, liver, lung, kidney, myoma, bone, etc. STARmed Co., Ltd. operates as a specification developer, manufacturer and distributor of innovative medical devices to cure patients with minimally invasive interventional therapy.

Come visit us at booth #17

Complications of lung biopsy
are no day at the beach

PROVEN PROTECTION AGAINST PNEUMOTHORAX & CHEST TUBES

52%	relative risk reduction in PTX
67%	relative risk reduction in chest tubes
35%	decrease in hospital admissions
NO	clinically significant complications associated with use



SURGICAL
SPECIALTIES
CORPORATION™

BIOSENTRY™
TRACT SEALANT SYSTEM

PLUG. PREVENT. PROTECT.

See BioSentry™ in action at BioSentrySystem.com

Surefire Medical, Inc.

8

6272 W. 91st Avenue
CO 80031 Westminster
United States
Phone: +1 303 426-1222
Fax: +1 303 426-1223
E-mail: info@surefiremedical.com
www.surefiremedical.com

Surefire Medical, Inc. develops, manufactures and markets targeted delivery devices for the interventional oncology market. Surefire's core technology consists of a microcatheter with a unique expandable tip that improves tumor uptake while protecting healthy tissue. It enables physicians to target tumors with superior accuracy, control and protection. Learn more: www.surefiremedical.com.

Surgical Specialties Corporation



17

50 Braintree Hill Office Park Suite 101
MA 02184 Braintree
United States
Phone: +1 781 602 6771
www.surgicalsurgicalspecialties.com

Surgical Specialties designs and manufactures high performance interventional radiology products, surgical knives and wound closure products. At ECIO, we are featuring the BioSentry™ Tract Sealant System, a fully reimbursed FDA-approved device with proven protection against pneumothorax and chest tube placement. Visit us at booth 17 to receive a demo and learn more.

Terumo

7-9 Rue Eugène et Armand Peugeot

92500 Rueil Malmaison

France

Phone: +33 1 47 16 09 46

Fax: +33 1 47 16 09 49

E-Mail: alexandra.vassiliades@terumo-europe.comwww.terumo-europe.com

DIAMOND



3

Founded in Tokyo in 1921, Terumo is a multinational company with more than 90 years' experience in developing best-in-class medical devices. Pushing boundaries is what drives us to support interventionalists to do more. Rising to the challenge of innovating for patients, Terumo brings you a complete range of interventional oncology products:

- Cutting-edge access and delivery systems (Occlusafe®, Radiofocus® Guidewire GT, Progreat®, Glidecath®)
- A complete range of embolic devices (AZUR® Peripheral HydroCoil®, AZUR® CX, HydroPearl®)
- Ablation systems (TATO TM) – coming soon
- SIRT next generation (QuiremSpheres® and Q-Suite TM manufactured by Quirem Medical) – coming soon
- Drug-eluting Microspheres (LifePearl®)

Having pioneered the field of interventional oncology, Terumo is relentlessly seeking new ways to help you to apply effective solutions and achieve better outcomes for your patients. We are committed to supporting our comprehensive product portfolio by a well-trained field force and a solid clinical evidence.

Toshiba Medical Systems Europe

13

Zilverstraat 1

2718RP Zoetermeer

The Netherlands

Phone: +31 611 526 311

E-mail: Jan.debruijn@toshiba-medical.eu

www.toshiba-medical.eu

For over 140 years Toshiba's research and development has improved the health and welfare of people around the world. Today, Toshiba Medical Systems offers a full range of diagnostic imaging products and is a reliable service partner in more than 135 countries around the globe. Our mission is to deliver the best quality products and services, as well as the industry's best after-sales support through long-term, customer focused partnerships.

Wisepress Medical Bookshop

19

15 Lyon Road, Merton

SW19 2RL London

United Kingdom

Phone: +44 20 8715 1812

E-mail: marketing@wisepress.com

www.wisepress.com

Wisepress.com, Europe's leading conference bookseller, attends around 200 conferences every year. We have an extensive range of books and journals relevant to the themes of this conference available at our booth. We also have a comprehensive range of STM titles available on our online bookshop. Follow us on Twitter @WisepressBooks.

Imprint

CIRSE Central Office

Neutorgasse 9
1010 Vienna, Austria

Phone: +43 1 904 2003

Fax: +43 1 904 2003 30

E-mail: info@cirse.org

www.ecio.org

The ECIO 2017 Pocket Guide

In case of any queries or comments,
please contact us at **info@cirse.org**

© Cardiovascular and Interventional Radiological Society of
Europe / 2017

GraphX by L O O P . E N T E R P R I S E S media
www.loop-enterprises.com

Print  kompensiert
Id-Nr. 1763325
www.druckmedien.at

 **MIX**
Paper from
responsible sources
FSC® C001924
www.fsc.org

 **NATURSTROM**
WWW.AAE.AT



Growing number of publications^{3,4,5}
Promising clinical results⁵

BECAUSE
EXPERIENCE
MATTERS

LifePearl®

Microspheres

- Enhanced suspension characteristics¹
- Tighter calibration²
- Syringe presentation

LifePearl is not available for sale in all countries. This information is provided only in respect to markets where this product is approved or cleared. LifePearl is cleared in US with indications for embolization of hypervascular tumors and arteriovenous malformations. LifePearl is not approved in Canada. Please contact your Terumo local sales representative for more information.

¹ Data on file. Ref. LPMC-V-004. Microvention, Inc. Comparison with Terumo's previously commercialized product.

² Data on file. Ref. LPMGT-002, LPMC-V-003, LPMC-V-004. Microvention, Inc. Comparison with Terumo's previously commercialized product.

³ Pereira PL, et al. An in vitro evaluation of three types of drug-eluting microspheres loaded with Irinotecan. Anticancer Drugs. 2016 Jul 12.

⁴ De Baere T, et al. An in vitro evaluation of four types of drug-eluting microspheres loaded with Doxorubicin. J Vasc Interv Radiol. 2016 Jul 8.

⁵ Alberts C, et al. Hepatic arterial infusion of polyethylene glycol drug-eluting beads for primary and metastatic liver cancer therapy. Anticancer Res. 2016 Jul; 36(7):3515-21.



ACCESS AND
DELIVERY SYSTEMS



ABLATION SYSTEMS



MICROSPHERES



RADIOEMBOLIZATION

AT THE
FOREFRONT OF
**INTERVENTIONAL
ONCOLOGY**
WITH YOU

PUSHING BOUNDARIES

TERUMO
INTERVENTIONAL
SYSTEMS

www.terumo-europe.com

